Key Points:
- Hong Kong conglomerate Jardine Matheson agreed to acquire Australia’s largest diagnostic imaging chain, I-MED Radiology, for A$3.4 billion (2.44 billion).
- The deal includes a minority stake in Harrison.ai, a pioneer in artificial intelligence tools for CT brain and chest scans.
- I-MED operates 215 clinics across Australia and New Zealand, performing over 7 million diagnostic procedures annually.
- Jardine Matheson will fund the transaction with existing cash reserves and debt, and expects the deal to close by late 2026.
Hong Kong-based conglomerate Jardine Matheson Holdings has agreed to acquire Sydney-based diagnostic imaging provider I-MED Radiology Network in a landmark deal valued at an enterprise value of A$3.4 billion (approximately $2.44 billion). The storied investment group, which traditionally focuses on property, retail, hotels, and automotive dealerships, is buying 100% of the company from funds advised by private equity firm Permira and other minority shareholders. This acquisition represents a massive expansion into the high-tech healthcare sector for the 190-year-old conglomerate.
The strategic acquisition gives Jardine Matheson a major foothold in the rapidly growing medical diagnostics and healthcare technology markets. I-MED operates a sprawling network of 215 diagnostic imaging clinics across metropolitan and regional communities in Australia and New Zealand. The company performs over 7 million patient procedures annually, establishing itself as the largest provider of medical imaging and teleradiology in the region. Teleradiology uses advanced secure networks to transmit medical scans remotely, allowing off-site specialists to read and diagnose patient cases from anywhere in the world.
Crucially, the transaction includes I-MED’s minority interest in Harrison.ai, a prominent Sydney-headquartered developer of artificial intelligence solutions for clinical radiology. Harrison.ai designs cutting-edge AI deep-learning models that automate the analysis of complex medical imaging, including CT brain scans, chest X-rays, and diagnostic mammograms. By securing this stake, Jardine Matheson positions itself directly at the center of the generative AI healthcare revolution, which developers expect will dramatically shorten patient wait times and improve diagnostic accuracy.
Under the leadership of Chief Executive Officer Lincoln Pan, who took the helm in December, Jardine Matheson is executing a long-term strategy of acquiring market-leading businesses with robust regional expansion potential. Pan explained that the group aims to utilize its patient capital to scale high-quality enterprises across the Asia-Pacific region. He expressed strong confidence in the business, stating that I-MED’s solid market leadership, exceptional earnings record, and highly capable management team make it an ideal vehicle to drive future regional expansion.
The financial metrics of the transaction reflect a highly disciplined capital allocation strategy. The purchase price values I-MED at approximately 11.5 times its forecast adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) for the 12 months ending June 2026, excluding the Harrison.ai holding. This valuation matches the robust growth profile of the target company. Over the five years ending June 2025, I-MED delivered consistent compound annual growth rates of 11% in revenue and 12% in adjusted EBITDA, underscoring the defensive, recession-proof nature of the diagnostic healthcare sector.
Jardine Matheson will fund the multi-billion-dollar acquisition with a balanced mix of existing cash reserves and newly secured debt facilities. The conglomerate stated that the transaction will remain neutral to its underlying earnings per share (EPS) in the first full year after completion, then become accretive to earnings in subsequent years. Crucially, the massive cash outlay will not disrupt the company’s near-term investor returns, as its existing dividend and underlying EPS guidance for the 2026 fiscal year remain completely unchanged.
Permira’s exit from I-MED marks the culmination of a highly successful private equity cycle. Permira originally purchased the Australian radiology provider in 2018 for a reported A$1.25 billion, subsequently investing millions of dollars to expand the clinic network, digitize client interfaces, and build the teleradiology business. By more than doubling the company’s enterprise value over an eight-year holding period, Permira demonstrated how private capital can successfully scale critical healthcare infrastructure before handing it off to long-term corporate stewards.
For the deal to be finalized, both parties must now secure the customary regulatory clearances. Because the transaction involves the transfer of vital domestic healthcare infrastructure and medical data, the Australian Foreign Investment Review Board (FIRB) must formally approve the takeover. Assuming regulators sign off on the transition, Jardine Matheson expects to complete the acquisition in full later in 2026. This landmark deal signals a major wave of consolidation in the global healthcare technology market, as massive conglomerates seek to acquire established, cash-generating medical platforms with advanced AI capabilities.
